Skip to main content
SpringerLink
Log in

Kommentar zum 2016 Positionspapier der Europäischen Gesellschaft für Kardiologie (ESC) zu kardiovaskulären Komplikationen onkologischer Therapien

Comments on the 2016 position paper of the European Society of Cardiology (ESC) on cardiovascular complications of oncological treatment

  • Positionspapier
  • Published:
Der Kardiologe Aims and scope

Zusammenfassung

Die Fortschritte in der onkologischen Behandlung führen dazu, dass Krebspatienten immer häufiger kardiovaskuläre Komplikationen ihrer onkologischen Therapie erleben. Außerdem haben viele der in den letzten Jahren neu entwickelten onkologischen Wirkstoffe potentielle kardiovaskuläre Nebenwirkungen. Anlässlich dieser zunehmend komplexeren kardio-onkologischen Überschneidungen hat die Europäische Gesellschaft für Kardiologie im August 2016 ein Positionspapier zu kardiovaskulären Komplikationen onkologischer Therapien publiziert. In diesem Dokument wurden systematisch die Pathogenese und klinische Manifestation kardiovaskulärer Krankheitsbilder im Kontext onkologischer Therapien zusammengefasst und Empfehlungsvorschläge für Screening, Diagnostik, Monitoring, Prävention und Therapie gegeben. In dem folgenden Kommentar, der gemeinsam von Vertretern der Deutschen Gesellschaft für Kardiologie und der Deutschen Gesellschaft für Hämatologie und medizinische Onkologie verfasst wurde, werden die wichtigsten Aspekte des Positionspapiers zusammengefasst und kritisch bewertet.

Abstract

Resulting from advances in oncological treatment, cancer patients frequently experience cardiovascular complications of the cancer treatment. Furthermore, many of the recently developed new drugs in oncology are potentially associated with cardiovascular side effects. Given this increased complexity in the field of cardio-oncology, the European Society of Cardiology published a position paper on cancer treatment and cardiovascular toxicity in August 2016. This position paper for the first time systematically reviewed the pathophysiology and clinical manifestations of cardiovascular disease entities during and after cancer treatment and provided suggestions for screening, diagnosis, monitoring, prevention and treatment. The following comments of the German Society of Cardiology in cooperation with the German Society of Hematology and Medical Oncology briefly summarizes and critically reviews the important aspects of the position paper.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2016/05/WC500206482.pdf. 2016. Zugegriffen: 1. Jul. 2017

  2. Mullard A (2016) 2015 FDA drug approvals. Nat Rev Drug Discov 15:73–76

    Article  CAS  Google Scholar 

  3. Zamorano JL, Lancellotti P, Rodriguez MD et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801

    Article  Google Scholar 

  4. Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200

    Article  Google Scholar 

  5. Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717

    Article  Google Scholar 

  6. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879

    Article  CAS  Google Scholar 

  7. Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B‑31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2‑positive breast cancer. J Clin Oncol 30:3792–3799

    Article  CAS  Google Scholar 

  8. Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15:1063–1093

    Article  Google Scholar 

  9. Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755

    Article  Google Scholar 

  10. NCI (2017) NCI Dictionary of Cancer Terms. Definition of cardiotoxicity. http://www.cancer.gov/dictionary?CdrID=44004%3E. Zugegriffen: 31. Okt. 2015

    Google Scholar 

  11. FDA (2017) FDA Drug Label for DOXIL-doxorubicin hydrochloride injection, suspension, liposomal. http://dailymed.nlm.nih.gov.ezproxy.hsclib.sunysb.edu/dailymed/drugInfo.cfm?setid=21d9c619-7e94-49e2-ac41-31e9ea96554a%3E. Zugegriffen: 31. Okt. 2015

    Google Scholar 

  12. Armenian SH, Lacchetti C, Barac A et al (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35:893–911

    Article  Google Scholar 

  13. Armenian SH, Hudson MM, Mulder RL et al (2015) Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16:e123–e136

    Article  Google Scholar 

  14. Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474–2481

    Article  CAS  Google Scholar 

  15. Shanafelt TD, Parikh SA, Noseworthy PA et al (2017) Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma 58:1630–1639

    Article  CAS  Google Scholar 

  16. Brown JR, Moslehi J, O’Brien S et al (2017) Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica 102(10):1796–1805

    Article  CAS  Google Scholar 

  17. Soignet SL, Frankel SR, Douer D et al (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852–3860

    Article  CAS  Google Scholar 

  18. Konstantinides SV, Torbicki A, Agnelli G et al (2014) 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033–3069k

    Article  CAS  Google Scholar 

  19. Gauter-Fleckenstein B, Israel CW, Dorenkamp M et al (2015) DEGRO/DGK guideline for radiotherapy in patients with cardiac implantable electronic devices. Strahlenther Onkol 191:393–404

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Kerpener Str. 62, 50935, Köln, Deutschland

    R. Pfister & S. Baldus

  2. Klinik für Innere Medizin, Universität Erlangen-Nürnberg, Erlangen, Deutschland

    S. Achenbach

  3. Klinik für Innere Medizin, Universität Düsseldorf, Düsseldorf, Deutschland

    F. Bönner & M. Kelm

  4. Klinik für Innere Medizin III, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland

    O. J. Müller

  5. Klinik für Innere Medizin, Universität Heidelberg, Heidelberg, Deutschland

    O. J. Müller

  6. Klinik I für Innere Medizin, Universität zu Köln, Köln, Deutschland

    M. Hallek & M. Kochanek

  7. II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie und Knochenmarktransplantation mit Sektion Pneumologie), Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    C. Bokemeyer

  8. Klinik für Innere Medizin, Hämatologie/Onkologie und Palliativmedizin, Evangelisches Klinikum Bethel, Bielefeld, Deutschland

    F. Weißinger

  9. Klinik für Hämatologie, Onkologie und Tumorimmunologie, Charité Campus Benjamin Franklin, Universitätsmedizin Berlin, Berlin, Deutschland

    D. Lüftner

Authors
  1. R. Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Achenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Bönner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O. J. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Hallek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Kochanek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Weißinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Lüftner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Baldus
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Kelm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Pfister.

Ethics declarations

Interessenkonflikt

Den Interessenkonflikt der Autoren finden Sie online auf der DGK-Homepage unter http://leitlinien.dgk.org/ bei der entsprechenden Publikation.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

S. Baldus und M. Kelm für die Kommission für Klinische Kardiovaskuläre Medizin

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pfister, R., Achenbach, S., Bönner, F. et al. Kommentar zum 2016 Positionspapier der Europäischen Gesellschaft für Kardiologie (ESC) zu kardiovaskulären Komplikationen onkologischer Therapien. Kardiologe 12, 19–25 (2018). https://doi.org/10.1007/s12181-017-0209-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-017-0209-2

Schlüsselwörter

Keywords

Search

Navigation